Event-Driven Stocks

NOVARTIS AG

NVSNYSE

Healthcare · Pharmaceutical Preparations · V8 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗

Financials

SEC XBRL · annual

No structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).

FDA-approved drugs

openFDA · most recent
  • RHAPSIDOSep 30, 2025
  • VIJOICEApr 24, 2024
  • TAFINLARMar 16, 2023
  • PLUVICTOMar 23, 2022
  • LOCAMETZMar 23, 2022
  • PIQRAYMay 24, 2019
  • MAYZENTMar 26, 2019
  • EGATENFeb 13, 2019

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20264.5M3.5-0.3%
Apr 30, 20264.5M3.0-22.4%
Apr 15, 20265.8M3.9-7.5%
Mar 31, 20266.3M3.4-17.0%
Mar 13, 20267.5M2.5+10.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Recent SEC filings

All filings ↗

Event-driven situations (9)